Alnylam Puts Up $65M To End Tekmira Trade Secrets Battle
Alnylam Pharmaceuticals Inc. has agreed to pay $65 million to Tekmira Pharmaceuticals Corp. as part of a licensing agreement settling a lawsuit that accused it of misappropriating Tekmira's trade secrets related...To view the full article, register now.
Already a subscriber? Click here to view full article